Development and Validation of a Patient-Reported Oral Mucositis Symptom (PROMS) Scale
Overview
Authors
Affiliations
Background And Objective: Oral mucositis, a painful condition with potentially life-threatening sequelae, often develops in association with allogeneic bone marrow transplantation. This condition has an adverse impact on the oral-health-related quality of life of patients undergoing marrow transplantation therapy. The purpose of this study was to create and validate a Patient-Reported Oral Mucositis Symptom (PROMS) scale. This scale allows evaluation of symptoms of oral mucositis that threaten quality of life.
Materials And Methods: The PROMS scale was compared with previously validated tools measuring quality of life (Functional Assessment of Cancer Therapy--Bone Marrow Transplant), symptoms of depression (Center for Epidemiologic Studies Depression Scale), psychological well-being (Affect Balance Scale) and stressful life events, as well as an objective, clinician-rated assessment of oral mucositis (Visual Analogue Scale--Oral Mucositis Assessment Scale). Thirty-four patients who were to undergo allogeneic bone marrow transplantation at Princess Margaret Hospital in Toronto, Ontario, were enrolled in this validation study.
Results: The PROMS scale had high internal reliability, as well as good convergent and discriminant validity relative to subjective measures of well-being. Longitudinal assessments showed that changes in PROMS scores were strongly correlated with changes in clinical assessment of oral mucositis over the first 2 weeks after transplantation, when the onset of oral mucositis typically occurs and the lesions are most severe.
Conclusions: Oral mucositis in patients who have undergone bone marrow transplantation can be quantified reliably with the easily administered PROMS scale. The PROMSscale provides a valid measure of the impact of oral mucositis on the oral-health-related quality of life of patients affected by this malady.
Abdalla-Aslan R, Bonomo P, Keefe D, Blijlevens N, Cao K, Cheung Y EClinicalMedicine. 2024; 73:102675.
PMID: 38933098 PMC: 11200283. DOI: 10.1016/j.eclinm.2024.102675.
Jahanbani Mazraeh E, Sadighi S, Manifar S, Bakhshandeh H, Rajabi M Support Care Cancer. 2023; 31(8):497.
PMID: 37505326 DOI: 10.1007/s00520-023-07943-9.
Oral Mucosa in Cancer Patients-Putting the Pieces Together: A Narrative Review and New Perspectives.
Reuss J, Alonso-Gamo L, Garcia-Aranda M, Reuss D, Albi M, Albi B Cancers (Basel). 2023; 15(13).
PMID: 37444405 PMC: 10340546. DOI: 10.3390/cancers15133295.
Porzio G, Capela A, Giusti R, Lo Bianco F, Moro M, Ravoni G Drugs Context. 2023; 12.
PMID: 37077766 PMC: 10108666. DOI: 10.7573/dic.2022-11-7.
Wong S, Tan S, Danaee M, Muhamad K, Jamal M, Islahudin F Asia Pac J Oncol Nurs. 2023; 10(2):100180.
PMID: 36880090 PMC: 9985023. DOI: 10.1016/j.apjon.2022.100180.